KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) FCF Margin (2020 - 2023)

Historic FCF Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 370.87%.

  • AbCellera Biologics' FCF Margin fell 4571200.0% to 370.87% in Q4 2023 from the same period last year, while for Sep 2024 it was 2150.17%, marking a year-over-year decrease of 20148300.0%. This contributed to the annual value of 648.4% for FY2024, which is 3306500.0% down from last year.
  • Latest data reveals that AbCellera Biologics reported FCF Margin of 370.87% as of Q4 2023, which was down 4571200.0% from 309.7% recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' FCF Margin registered a high of 526.37% during Q2 2022, and its lowest value of 484.31% during Q1 2023.
  • Over the past 4 years, AbCellera Biologics' median FCF Margin value was 23.84% (recorded in 2021), while the average stood at 27.53%.
  • Per our database at Business Quant, AbCellera Biologics' FCF Margin surged by 2389100bps in 2021 and then tumbled by -5989400bps in 2023.
  • Over the past 4 years, AbCellera Biologics' FCF Margin (Quarter) stood at 0.11% in 2020, then tumbled by -17315bps to 18.76% in 2021, then skyrocketed by 560bps to 86.25% in 2022, then crashed by -530bps to 370.87% in 2023.
  • Its FCF Margin stands at 370.87% for Q4 2023, versus 309.7% for Q3 2023 and 72.57% for Q2 2023.